IBIO Archives - BioTuesdays

Developments

iBio adds ShieldTx to tech stack, enhances immune-oncology pipeline

iBio (NYSEA:IBIO) launched ShieldTx, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. The addition of...

November 3, 2023

Developments

iBio in pending deal to sell CDMO facility; extends Woodforest credit agreement

iBio (NYSEA:IBIO) announced a sixth amendment to its credit agreement with Woodforest National bank to allow sufficient time for the company to complete the pending sale of its cGMP biologics manufacturing facility. The...

September 22, 2023

Developments

iBio posts positive in vivo proof of concept in 3 immuno-oncology programs

iBio (NYSEA:IBIO) reported positive preclinical in vivo data for three immuno-oncology candidates – an anti-EGFRvIII, CCR8 and a bispecific TROP-2 x CD3 – advancing the three programs to clinical candidate...

August 14, 2023

Executive Moves

iBio names Dr. Martin Brenner and Felipe Duran as permanent CEO and CFO, respectively

iBio (NYSEA:IBIO) appointed Martin Brenner, DVM, Ph.D., as CEO and Felipe Duran as CFO, effective immediately. Dr. Brenner will also continue to serve as iBio’s CSO, a role he has held since December 2020. The...

June 27, 2023

Developments

iBio in pact with NIH to develop Lassa fever vaccine

iBio (NYSEA:IBIO) entered into a research collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), an arm of the National Institutes of Health (NIH), to investigate the potential of iBio’s...

June 12, 2023

Developments

iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline

iBio (NYSEA:IBIO) expanded its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for immuno-oncology applications. Through...

June 6, 2023

Developments

GEN highlights iBio pivot to precision antibody immunotherapies

Genetic Engineering & Biotechnology News (GEN), in a feature article, outlines iBio’s (NYSE American:IBIO) transition from a contract development and manufacturing organization and cGMP biologics manufacturer to a...

May 30, 2023

Developments

JMP sees Phase 1 results for Roche’s antibody encouraging for iBio’s IBIO-101

JMP Securities, in a new report, writes that the promising mechanistic and clinical activity for Roche’s drug candidate, RG6292, should support advancement of iBio’s (NYSEA:IBIO) IBIO-101. IBIO-101 is an anti-CD25...

April 17, 2023

Developments

iBio discovers new panel of CD3 T-cell binding antibodies using AI epitope steering platform

iBio (NYSEA:IBIO) announced the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the company into bispecific immuno-oncology therapies. T-cell-redirecting bispecific...

April 5, 2023

Developments

iBio advances anti-CCR8 antibody program; looks forward to Roche RG6292 data

iBio (NYSEA:IBIO) advanced its anti-CCR8 antibody immuno-oncology program into preclinical in vivo testing. CCR8, a member of the G protein-coupled receptor (GPCR) family, is expressed by T-regulatory cells (Tregs) that...

March 31, 2023

Tag - IBIO

iBio adds ShieldTx to tech stack, enhances immune-oncology pipeline

iBio in pending deal to sell CDMO facility; extends Woodforest credit agreement

iBio posts positive in vivo proof of concept in 3 immuno-oncology programs

iBio names Dr. Martin Brenner and Felipe Duran as permanent CEO and CFO, respectively

iBio in pact with NIH to develop Lassa fever vaccine

iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline

GEN highlights iBio pivot to precision antibody immunotherapies

JMP sees Phase 1 results for Roche’s antibody encouraging for iBio’s IBIO-101

iBio discovers new panel of CD3 T-cell binding antibodies using AI epitope steering platform

iBio advances anti-CCR8 antibody program; looks forward to Roche RG6292 data

General

More